New York, NY – Measuring the amount of glucosylsphingosine, also called lyso-Gb1, a key marker used to help diagnose Gaucher disease, may aid doctors in deciding when someone with Gaucher disease type 1 should begin treatment, a new study suggests. Additionally, a certain level of lyso-GL1 may help distinguish between...
research News
Baltimore, Maryland – Repeats of DNA sequences, often referred to as “junk DNA” or “dark matter,” that are found in chromosomes and could contribute to cancer or other diseases have been challenging to identify and characterize. Now, investigators at the Johns Hopkins Kimmel Cancer Center have developed a novel approach that uses...
Barcelona, Spain – Researchers from the Germans Trias i Pujol Research Institute (IGTP) have made progress in exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in cell models have been published in the journal JCI Insight. Neurofibromatosis type 1 is a rare genetic disorder that...
Stockholm, Sweden — Members of the AD-RIDDLE consortium announced today that they will begin a new initiative that aims to bridge the gap between Alzheimer’s research, implementation science, and precision medicine. The AD-RIDDLE programme will offer healthcare professionals a suite of validated solutions for timely detection and diagnosis of Alzheimer’s...
Bengaluru, India – The spread of tumour from the primary cancer site to distant organs, called metastasis, has puzzled scientists for many years – they are only now beginning to pinpoint triggers and mechanisms that drive this process. A new study from the Indian Institute of Science (IISc) shows how...
Birmingham, UK – Pathological abnormalities associated with motor neurone disease have been identified using a new technique developed at the University of Birmingham. The method will help scientists better understand the changes in the brain that lead to motor neurone disease (MND) and could eventually yield insights that will help...
WILMINGTON, Del. — Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization....
Barcelona, Spain – Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years. One of the factors contributing to its aggressiveness is its tumor microenvironment, known as the stroma, which makes up the majority of the tumor mass and...
LUND, Sweden — Hansa Biopharma today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment. In the trial, the primary endpoint was the...
Utrecht, Netherlands – A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the...